NEW YORK (

TheStreet

) --

Pharmaceutical Product Development

(Nasdaq:

PPDI

) hit a new 52-week high Tuesday as it is currently trading at $31.85, above its previous 52-week high of $31.75 with 123,985 shares traded as of 10:02 a.m. ET. Average volume has been 888,500 shares over the past 30 days.

Pharmaceutical Product Development has a market cap of $3.5 billion and is part of the

health care

sector and

health services

industry. Shares are up 11.7% year to date as of the close of trading on Monday.

Pharmaceutical Product Development, Inc., a contract research organization, provides drug discovery, development, and lifecycle management services. It operates in two segments, Development and Laboratory Services. The company has a P/E ratio of 30.1, below the average health services industry P/E ratio of 30.4 and above the S&P 500 P/E ratio of 16.7.

  • Practice your PPDI trading strategies and win cash in our stock game.

TheStreet Ratings rates Pharmaceutical Product Development as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full

Pharmaceutical Product Development Ratings Report

.

See all

52-week high stocks

or get investment ideas from our

investment research center

.

null